<DOC>
	<DOCNO>NCT00075686</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop tumor cell divide stop grow die . Monoclonal antibody , cetuximab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know whether gemcitabine effective without cetuximab treat pancreatic cancer . PURPOSE : This randomized phase III trial study give gemcitabine together cetuximab see well work compare give gemcitabine alone first-line therapy treat patient locally advance unresectable metastatic adenocarcinoma pancreas .</brief_summary>
	<brief_title>S0205 Gemcitabine w/ w/o Cetuximab First-Line Therapy Locally Advanced Pancreas Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient locally advance unresectable metastatic adenocarcinoma pancreas treat gemcitabine cetuximab v gemcitabine alone . - Compare time treatment failure patient treat regimen . - Estimate percentage patient epidermal growth factor receptor ( EGFR ) tumor expression patient treat regimen . - Compare overall survival patient EGFR-positive subset treat regimen . - Compare toxicity regimens patient . - Compare total response rate ( confirm unconfirmed complete partial response ) patient measurable disease treat regimen . - Compare patient report pain quality life patient treat regimen . OUTLINE : This open-label , randomize , multicenter study . Patients stratify accord disease status ( locally advance unresectable v metastatic ) , Zubrod performance status ( 0 1 v 2 ) , prior pancreatectomy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 gemcitabine IV 30 minute day 1 , 8 , 15 , 22 course 1 day 1 , 8 , 15 subsequent course . - Arm II : Patients receive gemcitabine arm I . In arm , course repeat every 4 week absence disease progression unacceptable toxicity . Quality life assess baseline , course , end study therapy . Patients follow every 6 month 2 year annually 1 year . PROJECTED ACCRUAL : A total 704 patient ( 352 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically* cytologically confirm pancreatic adenocarcinoma meeting 1 follow criterion : Locally advance unresectable disease Distant metastatic disease NOTE : If diagnosis base metastatic site histology must compatible pancreatic cancer Measurable nonmeasurable disease xray , scan , physical examination Tumor tissue must submit evaluation epidermal growth factor receptor expression study entry None follow tumor type allow : Endocrine tumor Lymphoma pancreas Ampullary cancer No know brain metastasis PATIENT CHARACTERISTICS : Age Not specify Performance status Zubrod 02 Life expectancy At least 3 month Hematopoietic Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2.0 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal Creatinine great 2.0 mg/dL Cardiovascular No significant history cardiac disease No uncontrolled hypertension No unstable angina No uncontrolled arrhythmia No congestive heart failure Other Not pregnant nursing Fertile patient must use effective contraception HIV negative No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently remission PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy advance pancreatic cancer No prior cetuximab therapy target epidermal growth factor pathway No prior chimerized murine monoclonal antibody therapy No concurrent anticancer immunotherapy Chemotherapy At least 6 month since prior adjuvant chemotherapy No prior chemotherapy chemoradiotherapy advance pancreatic cancer No prior gemcitabine No concurrent anticancer chemotherapy Endocrine therapy No prior hormonal therapy advance pancreatic cancer No concurrent anticancer hormonal therapy Radiotherapy See Chemotherapy At least 28 day since prior radiotherapy recover Prior palliative radiotherapy metastatic site allow No concurrent anticancer radiotherapy , include whole brain radiotherapy progressive disease ( i.e. , CNS metastasis ) Surgery At least 14 day since prior pancreatic cancer surgery recover Other No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>